Analytical Data
-
基因名
Serum Albumin/ALB
-
简介
Serum albumin (ALB) protein binds a variety of substances, including water, calcium, sodium, potassium, fatty acids, hormones, bilirubin, and drugs. It regulates blood osmolality and transports zinc, calcium and magnesium. Serum Albumin/ALB Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Serum Albumin/ALB protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
别名
Albumin; ALB; Serum albumin; ANALBA; FDAH; PRO0883; PRO0903; PRO1341
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A2V9Z4
-
表达区间
D25-A608
-
蛋白长度
Full Length of Mature Protein
-
分子量
66-70 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Serum Albumin (ALB) is the most abundant protein in human blood plasma, playing a crucial role in maintaining oncotic pressure, transporting various substances, and regulating pH levels. Recombinant human serum albumin (rHSA) has gained significant attention in biomedical research and pharmaceutical applications due to its potential benefits over native albumin, including reduced risk of contamination with pathogens and improved safety profiles. The production of rHSA offers advantages such as enhanced stability, modified pharmacokinetics, and tailored pharmacodynamics, making it an attractive option for drug delivery systems, therapeutic agents, and as a plasma substitute in clinical settings. Research has focused on optimizing the expression and purification processes of rHSA, utilizing various recombinant systems such as bacterial, yeast, or mammalian cells to achieve high yields and functional purity. Understanding the structure-function relationships of rHSA is essential for developing effective treatments for a range of conditions, including liver cirrhosis, burns, and sepsis, where albumin levels are critically low. The ongoing studies seek not only to improve the production methods but also to explore innovative applications of rHSA in targeted drug delivery, as well as its potential role in regenerative medicine and as an immune modulator. This research aims to bridge the gap between basic science and clinical application, ultimately contributing to improved therapeutic strategies and patient outcomes.
